IP Library Granted Patent US 6,979,470
Granted Patent B2
US 6,979,470 · App. 10/198,277 · Granted Dec 27, 2005

Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,979,470
App. No.
10/198,277
Granted
Dec 27, 2005
Kind
B2
Abstract

Compositions comprising an effective amount of a curcuminoid species and an effective amount of a diterpene lactone species, a triterpene species or derivatives thereof that have a synergistic effect on specific inhibition of inducible COX-2 activity and have minimal effect on COX-1 activity are disclosed. Methods of using the compositions for providing synergistic anti-inflammatory effects are also disclosed.

Claims (16)

1. A composition comprising an effective amount of curcumin and an effective amount of andrographolide, wherein the ratio of curcumin and andrographolide is from 1:10 to 10:1, said composition having at least 5 times less inhibitory activity on cyclooxygenase-1 (COX-1) than on cyclooxygenase-2 (COX-2).

2. The composition of claim 1 , wherein the curcumin is pharmaceutical grade curcumin.

3. The composition of claim 1 , wherein the andrographolide is pharmaceutical grade andrographolide.

4. The composition of claim 1 , wherein at least one of the curcumin or andrographolide is derived from a plant or plant extract.

5. The composition of claim 1 , wherein at least one of the curcumin or andrographolide is conjugated with a compound selected from the group consisting of mono- or disaccharides, amino acids, sulfates, succinate, acetate and glutathione.

6. The composition of claim 5 , wherein the conjugated compound is mono- or disaccharide.

7. The composition of claim 1 , said composition further comprising one or more members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, carbohydrates, glucosamine, chondrotin sulfate and aminosugars.

8. The composition of claim 7 , wherein said composition further comprises glucosamine.

9. A composition comprising an effective amount of curcumin and an effective amount of oleanolic acid, wherein the ratio of curcumin and oleanolic acid is from 1:10 to 10:1, said composition having at least 5 times less inhibitory activity on cyclooxygenase-1 (COX-1) than on cyclooxygenase-2 (COX-2).

10. The composition of claim 9 , wherein the curcumin is pharmaceutical grade curcumin.

11. The composition of claim 9 , wherein the oleanolic acid is pharmaceutical grade oleanolic acid.

12. The composition of claim 9 , wherein at least one of the curcumin or oleanolic acid is derived from a plant or plant extract.

13. The composition of claim 9 , wherein at least one of the curcumin or oleanolic acid is conjugated with a compound selected from the group consisting of mono- or di-saccharides, amino acids, sulfates, succinate, acetate and glutathione.

14. The composition of claim 13 , wherein the conjugated compound is mono- or di-saccharide.

15. The composition of claim 9 , said composition further comprising one or more members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, carbohydrates, glucosamine, chondrotin sulfate and aminosugars.

16. The composition of claim 15 , wherein said composition further comprises glucosamine.

Assignments (5)
TERMINATION AND RELEASE OF PATENT SECURITY AGREEMENT - REEL/FRAME 057981/0156 Recorded Dec 24, 2025
From: FORTRESS CREDIT CORP.
To: METAGENICS LLC (FKA METAGENICS, INC.); METAPROTEOMICS, LLC
Reel/Frame 074057/0392 →
TERMINATION AND RELEASE OF PATENT SECURITY AGREEMENT - REEL/FRAME 058015/0602 Recorded Dec 23, 2025
From: FORTRESS CREDIT CORP.
To: METAGENICS LLC (FKA METAGENICS, INC.); METAPROTEOMICS, LLC
Reel/Frame 074050/0670 →
SECURITY INTEREST Recorded Nov 4, 2021
From: METAGENICS, INC.; METAPROTEOMICS, LLC
To: FORTRESS CREDIT CORP. (AS COLLATERAL AGENT)
Reel/Frame 058015/0602 →
SECURITY INTEREST Recorded Nov 1, 2021
From: METAGENICS, INC.; METAPROTEOMICS, LLC
To: FORTRESS CREDIT CORP., AS COLLATERAL AGENT
Reel/Frame 057981/0156 →
RELEASE OF SECURITY INTEREST Recorded Oct 25, 2021
From: BANK OF AMERICA, N.A.
To: META PROTEOMICS, LLC
Reel/Frame 057909/0199 →